Similar posts:

• 
  AbbVie Submits Biologics License Application to U.S. FDA of a new botulinum toxin type E

  AbbVie has submitted an application to the FDA for the approval of TrenibotE — the first-in-class botulinum toxin type E. The product demonstrates a record-fast onset of action (8 hours) and a short duration of effect (2-3 weeks), which may change the approach to initial injections in patients who have previously avoided neurotoxins.

• 
  Botox or Dysport?

  People often ask me what I prefer: Botox or Dysport? My answer is unoriginal: I love both of these products. But it’s important that the love is mutual.

• 
  Informed Consent for Botox Injection

  Sample informed consent form for the administration of Botox.